Joe McCann
Founder at POINT Biopharma Corp.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Neil Fleshner | M | 60 |
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
POINT Biopharma Corp.
 POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The private company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 5 years |
| Allan Silber | M | 75 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The private company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 5 years |
| Jonathan Goodman | M | 56 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The private company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 4 years |
| Justyna Kelly | F | 39 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 3 years |
| Margaret Gilmour | F | 64 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Emma Walmsley | F | 55 | 14 years | |
| Ari Shomair | M | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | - |
| William Demers | M | 66 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Gerald Hogue | M | 66 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Michael Thompson | M | - | 1 years | |
| Michael Gottlieb | M | 45 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Peggy Gilmour | F | - |
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The private company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Gerry Hogue | M | - |
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The private company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Howard M. Glase | M | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The private company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 4 years |
| Jessica Jensen | F | 44 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Philip Johnson | M | 59 | 1 years | |
| María Cristina de Luna Basagoiti | F | - | 14 years | |
| Anita Kidgell | F | - | 16 years | |
| Gordon Brooks | M | - | 1 years | |
| Victoria Whyte | F | - | 15 years | |
| Chris Anderson | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephanie Burns | M | 69 | 9 years | |
| Bridget Martell | M | 58 | - | |
| Roy Anderson | M | 76 | 11 years | |
| Daniel Podolsky | M | 70 | 10 years | |
| Yael Margolin | M | 70 | 2 years | |
| Christopher Viehbacher | M | 64 | 20 years | |
| David Lubner | M | 60 | 2 years | |
| Rajesh K. Malik | M | 65 | 2 years | |
| Jean-Pierre Garnier | M | 75 | 8 years | |
| James Murdoch | M | 51 | 3 years | |
| Ian Maurice Gray Prosser | M | 81 | 9 years | |
| Andrew Milne | M | 50 | 1 years | |
| Donna Husack | F | - | 3 years | |
| Vincent O'Neill | M | 55 | 3 years | |
| Jeffrey Skolnik | M | - | 5 years | |
| Amrik Basran | M | - | 3 years | |
| Alasdair B. James | M | 53 | 6 years | |
| Manuel Alves Aivado | M | 53 | 6 years | |
| Imran Eba | M | - | 4 years | |
| Neil Brewis | M | 57 | 8 years | |
| Lon Cardon | M | - | 9 years | |
| Raman Singh | M | 53 | 3 years | |
| Johan Heylen | M | 56 | 4 years | |
| Lynne Bulger | F | - | 5 years | |
| Paul Schaffer | M | - |
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | 3 years |
| Martin Andrews | M | 61 | 10 years | |
| David Gordon | M | 55 | 11 years | |
| Chao Hong Hu | M | 58 | 1 years | |
| Melita Sequeira | F | - | - | |
| Chris Horvath | M | - | 1 years | |
| Tonya Williams | F | 50 | 1 years | |
| Sherin Al-Safadi | M | - | - | |
| Robin Hallett | M | - | - | |
| Jing Ji | M | 54 | 4 years | |
| Clare Khan | M | 72 | 11 years | |
| Daniel Pearlstein | M | - | 2 years | |
| Myra Rosario Herrle | M | - | 2 years | |
| Muhammad Al-Hajj | M | 53 | 6 years | |
| David Chang | M | 61 | 8 years | |
| Jay C. Strum | M | - | 14 years | |
| Jeff McLaughlin | M | - | - | |
| Jack Bailey | M | 59 | 10 years | |
| Gregg Brandyberry | M | - | 16 years | |
| Matthew Vincent | M | - | 1 years | |
| Catherine Sohn | M | 71 | 28 years | |
| Gary W. Christianson | M | 69 | 2 years | |
| John Donofrio | M | 56 | 4 years | |
| Ellen Strahlman | M | 66 | 4 years | |
| Simon Harford | M | 64 | 8 years | |
| Elyse G. Seltzer | M | 59 | 6 years | |
| Atul Pande | M | 69 | 7 years | |
| Jeff Baxter | M | 62 | 4 years | |
| Russell Greig | M | 71 | 7 years | |
| Yvonne Greenstreet | M | 61 | 2 years | |
| Marc Dunoyer | M | 71 | 3 years | |
| Stephen A. Ross | M | 54 | 5 years | |
| Ronaldo Hermann Schmitz | M | 85 | 9 years | |
| Michael D. Rogers | M | 68 | 6 years | |
| M. Berrey | M | 57 | 3 years | |
| Deirdre Connelly | F | 63 | 6 years | |
| Annette Clancy | F | 70 | 30 years | |
| Jayant Aphale | M | 63 | - | |
| Michael Owen | M | 73 | 9 years | |
| Roger Xie | M | 54 | 1 years | |
| John B. Elliot | M | 72 | 5 years | |
| Paolo Augusto Paoletti | M | 73 | 7 years | |
| Anne Michelle Whitaker | F | 56 | 3 years | |
| Maxine Gowen | M | 66 | 2 years | |
| Bing Li | M | 55 | 4 years | |
| Claire Thomas | F | - | - | |
| Eric Burak | M | - |
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | 5 years |
| Dan Troy | M | 64 | 10 years | |
| David M. Pernock | M | 69 | 16 years | |
| Carol Ashe | F | 66 | 13 years | |
| Shah Hussain | M | 59 | 9 years | |
| Stephen F. Stefano | M | 68 | 29 years | |
| David Pompliano | M | - | 5 years | |
| Mark Berger | M | 69 | 5 years | |
| Thyagi Thyagarajan | M | - | 38 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 69 | 69.00% |
| United States | 29 | 29.00% |
| Canada | 8 | 8.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joe McCann
- Personal Network
